Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Challenging Cases in Lung Cancer: Stage IIIA N2 Node-Positive NSCLC, Debatably Resectable
Author
Howard (Jack) West, MD

As part of the series co-sponsored by GRACE and LUNGevity, challenging cases in lung cancer discussed with multiple experts, here's one on the common but vexing scenario of a patient with mediastinal node-positive (stage IIIA N2) NSCLC. This is among the most controversial clinical settings in lung cancer, as illustrated by the wide range of answers of how the experts in this program would manage the same patient. Some of the experts even note that the way that such a patient would be managed at their center would depend on the people weighing in on the case. This also underscores how important a multidisciplinary approach, often developed in a "tumor board" conference, is for developing treatment plans, ideally by a consensus among the various medical specialists involved.

Here's the audio podcast, video podcast, and transcript for the program (really not much video to follow for this one).

[powerpress]

grace-cases-stage-iiia-n2-nsclc-of-questionable-resectability-audio-podcast

grace-cases-stage-iiia-n2-nsclc-of-questionable-resectability-transcript

We'd love to hear your comments and questions.

There are still several more interesting cases in this series, but we'll take a break from them for a while to bring you the podcasts for the ASCO Lung Cancer Highlights webinar from a couple of weeks ago. Look for those over the next couple of weeks.

And thanks again to LUNGevity Foundation for their support in developing the case series, the ASCO highlights program, and the podcasts for all of these activities!

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Hi Hopish hope,  Welcome to…
By JanineT GRACE … on
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on